TransMedics Group, Inc. Stock Analysis & AI Score
TransMedics Group, Inc. (TMDX) has an ST Score of 48.9 (C+), driven by its Profitability (A) and held back by its Valuation (F). Analysts rate it Buy with a $99.63 price target (+33.3% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
AI Daily Briefing
Analysis by AITMDX Stock Price History
TMDX Technical Indicators
FMPEarnings Surprises
Analyst Forecast
Revenue Mix
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Medical - Devices |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Analyst Price Target
ESG Score
TMDX Latest Stock News
ST Score
TransMedics Group, Inc. (TMDX) has an ST Score of 48.9 (C+), driven by its Profitability (A) and held back by its Valuation (F). Analysts rate it Buy with a $99.63 price target (+33.3% upside).
- Strongest
- ProfitabilityA
- Weakest
- ValuationF
All factor grades
- ProfitabilityA
- GrowthB+
- Financial StrengthB-
- ForecastB-
- MomentumC-
- ValuationF
- Piotroski4/9
Press Releases
Company Contact Details
TMDX stock: frequently asked questions
What is TMDX's ST Score?
TransMedics Group, Inc. (TMDX) has an ST Score of 48.9 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is TMDX a buy, hold, or sell?
Analysts rate TMDX a Buy, with a price target of $99.63 (+33.3% vs the current price). Our ST Score grades it C+ (48.9/100). The ST Score is a data-driven signal, not a recommendation.
What are TMDX's factor grades?
Valuation F, Profitability A, Financial Strength B-, Momentum C-, Growth B+, Forecast B-.
What is TMDX's valuation grade?
TransMedics Group, Inc. (TMDX) earns a valuation grade of F, measured against Medical - Devices peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is TMDX's growth grade?
TransMedics Group, Inc. (TMDX) earns a growth grade of B+, measured against Medical - Devices peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is TMDX's profitability grade?
TransMedics Group, Inc. (TMDX) earns a profitability grade of A, measured against Medical - Devices peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is TMDX's financial strength grade?
TransMedics Group, Inc. (TMDX) earns a financial strength grade of B-, measured against Medical - Devices peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for TMDX?
The average analyst price target for TransMedics Group, Inc. (TMDX) is $99.63 from 13 analysts, which is +33.3% versus the recent price of $74.75.
What is TMDX's Piotroski score?
TransMedics Group, Inc. (TMDX) has a Piotroski F-Score of 4 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.